Powering AI-Driven Drug Discovery with President of Isomorphic Labs Max Jaderberg
Elad Gil interviews Max Jaderberg, President of Isomorphic Labs, about how deep learning foundation models are transforming pharmaceutical drug discovery from empirical trial-and-error into precision in silico engineering. They discuss overcoming biopharma's long-standing productivity stagnation, phasing out animal testing with predictive AI and synthetic human tissues, structuring cross-disciplinary AI-biology teams, and utilizing precision molecule design to target complex diseases and human aging.
- Eradicating both cancer and heart disease would extend average human lifespan by only 5 to 7 years, because underlying cellular decay continues unchecked. Read →
- Biopharma's core delay is physical: synthesizing real atoms and culturing biological cells creates an expensive, slow trial-and-error cycle. Read →
- Annual drug approvals have stayed roughly flat for decades, even as scientific publications, budgets, and therapeutic modalities grew exponentially. Read →
- Rat models only predict human clinical toxicity roughly 30% of the time, leading to widespread failure when drug candidates reach human trials. Read →
- True cross-disciplinary unicorns who master both frontier deep learning and wet-lab biochemistry do not exist in meaningful volume; companies must hire pure specialists from each camp and build fluency internally. Read →